Basf Se Corporation

Ciba Specialty Chemicals Corporation

Empa Eidgenossische Materialprufungs-und Forschungsanstalt

Skynative Ug

Udc Ireland Limited

Tobias Hintermann

Andreas Hafner

Tiziana Chiodo

Beate Salvador

Marcus Vossen

Fritz Blatter

Martin Szelagiewicz

Peter Murer

Antoine Carroy

Caroline Lordelot

Peter Nesvadba

Andreas Kramer

Hitoshi Yamato

Toshikage Asakura

Didier Bauer

Bernd Siebenhaar

Rachel Kohli Steck

Andre Kostro

Cristobal Garrido Segura

Patrice Bujard

Beat Schmidhalter

Thomas Schäfer

Akira Matsumoto

Marie-Odile Zink

Martin Viertelhaus

Walter Weishaar

Rolf Hellmann

Adrian Von Muehlenen

Eva Roedel

Olof Wallquist

Peter Hoffmann

Wolfgang Schrof

Werner-Alfons Jung

Kristina Bardon

Andreas Mühlebach

Jochen Fink

Thomas Meier

Marc Faller

Lucienne Bugnon

Roman Fasel

Pascal Ruffieux

Jinming Cai

Eva Rödel

Christian Michael Jung

Juan Ramon Sanchez Valencia

Tatjana Vetter

A daylight illumination system for integration into a building or larger vehicle comprises a translucent facade element () containing a glass sheet and a light redirection element (or), and a light transport channel () for guiding light about horizontally into an interior of the building, the light transport channel comprising one opening attached to the interior side of said facade element and at least one opening towards the interior of the building, characterised in that the light redirection element (or) is formed as a structured polymer film or sheet attached to a glass sheet of the facade element () and is configured for changing the direction of incident light into the about horizontal light transport channel.

Daylighting illumination system

A daylighting panel for integration into a building or larger vehicle comprises a translucent facade element () containing a glass sheet and a light transport channel () for guiding light about horizontally into an interior of the building, the light transport channel comprising one opening attached to the interior side of said facade element and at least one opening towards the interior of the building equipped with a luminaire (), characterised in that the inner walls including the rear end are covered by a reflecting layer ().

Daylighting panel

The present invention provides a photolatent Ti-chelate catalyst formulation, comprising (i) at least one compound of the formula (I) wherein Ris C-Calkyl or C-Calkyl which is interrupted by one or more non-consecutive O-atoms; Y is formula (II) or optionally substituted phenyl; Yis formula (III) or optionally substituted phenyl; Yis formula (IV) or optionally substituted phenyl; Yis formula (V) or optionally substituted phenyl; R, R, R, R, R, R, R, R, R, R, Rand Rindependently of each other are hydrogen, halogen, optionally substituted C-Calkyl, or R, R, R, R, R, R, R, R, R, R, Rand Rindependently of each other are optionally substituted C-Caryl, provided that only one of R, R, Ris hydrogen and only one of R, R, Ris hydrogen and only one of R, R, Ris hydrogen and only one of R, R, Ris hydrogen; and (ii) at least one chelate ligand compound of the formula IIa, IIb or IIc, wherein Y' is formula (VI) or formula (VII); Y&#x2032;is formula (VIII) or formula (IX); R&#x2032;, R&#x2032;, R&#x2032;, R&#x2032;, R&#x2032;and R&#x2032;independently of each other have on of the meanings as given for R, R, R, R, R, R, R, R, R, R, Rand R; and R&#x2032;, R&#x2032;and R&#x2032;independently of each other have on of the meanings as given for R, Rand R. 

Photo-latent titanium catalysts

The present invention primarily relates to multi-component crystals comprising a compound of formula 1 and a second compound selected from the group consisting of co-crystal formers and solvents. The invention is further related to pharmaceutical compositions comprising such multi-component crystals. Furthermore, the invention relates to processes for preparing said multi-component crystals. The invention also relates to several aspects of using said multi-component crystals or pharmaceutical compositions to treat a disease.

Multi-component crystals of vismodegib and selected co-crystal formers or solvents

Combinations of (3&#x3b2;)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acid are useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.

Solid form of abiraterone acetate

The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

Salts of dasatinib in amorphous form

A titanium-oxo-chelate catalyst formulation, comprising: (i) at least one compound of the formula (I), wherein R, R, R, R, R, R, R, R, R, R, Rand Rindependently of each other are for example hydrogen, halogen, C-Calkyl, C-Caryl which is unsubstituted or substituted; or R, Rand Rand/or R, Rand Rand/or R, Rand Rand/or R, Rand Rtogether with the C-atom to which they are attached each form a C-Caryl group which is unsubstituted or substituted; or Rand Rand/or Rand Rand/or Rand Rand/or Rand Rtogether with the C-atom to which they are attached form a 5- to 7-membered carbocyclic ring; at least one chelate ligand compound of the formula (IIa), (IIb) or (IIc), wherein R, R, R, R, Rand Rare defined as above for formula (I), is suitable as photolatent catalyst formulation for polymerizing compounds, which are capable to crosslink in the presence of a Lewis acid. 

Photo-latent titanium-oxo-chelate catalysts

The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.

Multicomponent crystalline system comprising nilotinib and selected co-crystal formers

The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

Salts of Dasatinib in crystalline form

The present invention relates to a process for preparing a graphene nanoribbon, which comprises: (a) providing at least one aromatic monomer compound which is selected from at least one polycyclic aromatic monomer compound, at least one oligo phenylene aromatic monomer compound, or combinations thereof, on a solid substrate, (b) polymerization of the aromatic monomer compound so as to form at least one polymer on the surface of the solid substrate, (c) at least partially cyclodehydrogenating the one or more polymers of step (b), wherein at least step (b) is carried out at a total pressure p(total) of at least 1&#xd7;10mbar; and a partial oxygen pressure p(O) and partial water pressure p(HO) which satisfy the following relation: p(O)&#xd7;p(H20)&#x3c;3&#xd7;10mbar.

Process for preparing graphene nanoribbons

Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (1R,2S,5R)-(&#x2212;)-menthol. 

Multicomponent crystals comprising dasatinib and selected co-crystal formers

Described is a method and an apparatus for producing cured coating films on a substrate surface. Specifically, a portable spraygun may be used to initiate radiation cure without the operative having to be protected from radiation. The spraygun comprises a supply channel for a radiation-curable coating composition, a needle, a reserve for the radiation-curable coating composition, and, optionally, a supply channel for a gas.

Spraygun for producing cured coating films and methods of use thereof

The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN: Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same. 

Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof

Novel solid forms of imatinib mesilate comprising as active ingredient 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]-benzamide methanesulfonic acid salt and as co-crystal former benzoic acid, fumaric acid or succinic acid are described. The said multi-component crystalline forms possess improved physical and biological properties with respect to the crystalline forms of the active pharmaceutical ingredient previously known.

Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers

Growing community of inventors

Therwil, Switzerland

Tobias Hintermann